TAK1 control of cell death

被引:223
|
作者
Mihaly, S. R. [1 ]
Ninomiya-Tsuji, J. [1 ]
Morioka, S. [1 ]
机构
[1] N Carolina State Univ, Dept Biol Sci, Raleigh, NC 27695 USA
来源
CELL DEATH AND DIFFERENTIATION | 2014年 / 21卷 / 11期
关键词
NF-KAPPA-B; ACTIVATED KINASE 1; MIXED LINEAGE KINASE; PROTEIN-KINASE; IKK-BETA; MEDIATED APOPTOSIS; EPIDERMAL-KERATINOCYTES; TAK1-BINDING PROTEIN-2; POLYUBIQUITIN-BINDING; PREVENTS INFLAMMATION;
D O I
10.1038/cdd.2014.123
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Programmed cell death, a physiologic process for removing cells, is critically important in normal development and for elimination of damaged cells. Conversely, unattended cell death contributes to a variety of human disease pathogenesis. Thus, precise understanding of molecular mechanisms underlying control of cell death is important and relevant to public health. Recent studies emphasize that transforming growth factor-beta-activated kinase 1 (TAK1) is a central regulator of cell death and is activated through a diverse set of intra- and extracellular stimuli. The physiologic importance of TAK1 and TAK1-binding proteins in cell survival and death has been demonstrated using a number of genetically engineered mice. These studies uncover an indispensable role of TAK1 and its binding proteins for maintenance of cell viability and tissue homeostasis in a variety of organs. TAK1 is known to control cell viability and inflammation through activating downstream effectors such as NF-kappa B and mitogen-activated protein kinases (MAPKs). It is also emerging that TAK1 regulates cell survival not solely through NF-kappa B but also through NF-kappa B-independent pathways such as oxidative stress and receptor-interacting protein kinase 1 (RIPK1) kinase activity-dependent pathway. Moreover, recent studies have identified TAK1's seemingly paradoxical role to induce programmed necrosis, also referred to as necroptosis. This review summarizes the consequences of TAK1 deficiency in different cell and tissue types from the perspective of cell death and also focuses on the mechanism by which TAK1 complex inhibits or promotes programmed cell death. This review serves to synthesize our current understanding of TAK1 in cell survival and death to identify promising directions for future research and TAK1's potential relevance to human disease pathogenesis.
引用
收藏
页码:1667 / 1676
页数:10
相关论文
共 50 条
  • [41] TAK1 prevents TRAIL-induced cell death through an NF-κB-independent mechanism
    Morioka, Sho
    Omori, Emily
    Kajino, Taisuke
    Kajino-Sakamoto, Pie
    Matsumoto, Kunihiro
    Ninomiya-Tsuji, Jun
    FASEB JOURNAL, 2008, 22
  • [42] TAK1 inhibition for treatment of cerebral ischemia
    Ridder, Dirk A.
    Schwaninger, Markus
    EXPERIMENTAL NEUROLOGY, 2013, 239 : 68 - 72
  • [43] TAK1 in Vascular Signaling: "Friend or Foe"?
    Fan, Gang
    Lu, Jingfen
    Zha, Jinhui
    Guo, Weiming
    Zhang, Yifei
    Liu, Yuxin
    Zhang, Liyuan
    JOURNAL OF INFLAMMATION RESEARCH, 2024, 17 : 3031 - 3041
  • [44] Inhibition of TAK1 by kamebakaurin in dendritic cells
    Kim, Jee Youn
    Kim, Hyung Sook
    Kim, Yeon Jin
    Lee, Hong Kyung
    Kim, Ji Sung
    Kang, Jong Soon
    Hong, Jin Tae
    Kim, Youngsoo
    Hwang, Bang Yeon
    Han, Sang-Bae
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2013, 15 (01) : 138 - 143
  • [45] The role of TAK1 expression in thyroid cancer
    Lin, Pengfei
    Niu, Weibo
    Peng, Cheng
    Zhang, Zhaoyang
    Niu, Jun
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2015, 8 (11): : 14449 - 14456
  • [46] Expression and function of TAK1 in osteosarcoma tissue
    Wei, Yuxi
    Zhou, Ruiming
    Wang, Quanbing
    Fu, Beibei
    Jing, Weili
    Wang, Honglin
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (06): : 10891 - 10898
  • [47] Oxindole derivatives as inhibitors of TAK1 kinase
    Lockman, Jeffrey W.
    Reeder, Matthew D.
    Robinson, Rosann
    Ormonde, Patricia A.
    Cimbora, Daniel M.
    Williams, Brandi L.
    Willardsen, J. Adam
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (06) : 1724 - 1727
  • [48] TAK1 is a druggable kinase for diffuse large B-cell lymphoma
    Wu, Yuanyuan
    Yang, Riyun
    Ming, Yue
    Xu, Yuanpei
    Chen, Hao
    Yao, Min
    Chen, Xia
    Mao, Renfang
    Fan, Yihui
    CELL BIOCHEMISTRY AND FUNCTION, 2019, 37 (03) : 153 - 160
  • [49] TAK1 regulates Paneth cell integrity partly through blocking necroptosis
    Simmons, A. N.
    Kajino-Sakamoto, R.
    Ninomiya-Tsuji, J.
    CELL DEATH & DISEASE, 2016, 7 : e2196 - e2196
  • [50] Suppression of Tak1 Promotes Prostate Tumorigenesis
    Wu, Min
    Shi, Lihong
    Cimic, Adela
    Romero, Lina
    Sui, Guangchao
    Lees, Cynthia J.
    Cline, J. Mark
    Seals, Darren F.
    Sirintrapun, Joseph S.
    McCoy, Thomas P.
    Liu, Wennuan
    Kim, Jin Woo
    Hawkins, Gregory A.
    Peehl, Donna M.
    Xu, Jianfeng
    Cramer, Scott D.
    CANCER RESEARCH, 2012, 72 (11) : 2833 - 2843